You are here: Industry Insights > Sotrovimab

News List

WHO recommends GSK-Vir and Lilly’s drugs for Covid-19 treatment Pharmaceutical-Technology
January 17, 2022
The World Health Organization (WHO) has recommended the use of two new drugs by GlaxoSmithKline (GSK) and Vir Biotechnology and Eli Lilly to treat Covid-19.
GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab WorldPharmaNews
January 17, 2022
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) announced that the US Government will purchase an additional 600,000 doses of sotrovimab...
Canada to procure GSK’s Covid-19 antibody therapy doses Pharmaceutical-Technology
January 07, 2022
In October last year, GSK signed purchase agreement with Canada to supply 10,000 doses of Sotrovimab.
EC grants marketing authorisation to GSK-Vir’s Xevudy for Covid-19 Pharmaceutical-Technology
December 21, 2021
The European Commission (EC) has granted marketing authorisation to GlaxoSmithKline (GSK) and Vir Biotechnology’s Xevudy (sotrovimab) to treat Covid-19 in the early stage.
GSK Singapore Announces Additional Supply of Monoclonal Antibody Sotrovimab to the Government of Singapore prnasia
December 07, 2021
GlaxoSmithKline Singapore announced an agreement with the Government of Singapore to supply additional doses of sotrovimab. Sotrovimab is an investigational single-dose monoclonal antibody developed in partnership...
UK’s MHRA grants authorisation for GSK-Vir Biotechnology’s Covid-19 drug Pharmaceutical-Technology
December 06, 2021
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorisation for GSK and Vir Biotechnology’s investigational Covid-19 therapy, Xevudy (sotrovimab).
MHRA approves Xevudy (sotrovimab) to treat COVID-19 EuropeanPharmaceuticalReview
December 03, 2021
The Medicines and Healthcare products Regulatory Agency (MHRA) approve sotrovimab for people with mild to moderate COVID-19 infection and at least one risk factor for developing severe illness.
GSK and Vir Biotechnology announce United States government agreements to purchase sotrovimab, a COVID-19 treatment WorldPharmaNews
November 22, 2021
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) announced US government contracts totalling approximately $1 billion[1] (USD) to purchase sotrovimab...
GSK and Vir to supply Covid-19 antibody treatment doses to US Pharmaceutical-Business-Review
November 19, 2021
GlaxoSmithKline (GSK) and Vir Biotechnology have secured contracts from the US government for nearly $1bn to supply their Covid-19 antibody treatment, sotrovimab.
US agrees to procure doses of GSK-Vir’s Covid-19 therapy sotrovimab Pharmaceutical-Technology
November 19, 2021
The US Government has entered an agreement to procure doses of GlaxoSmithKline (GSK) and Vir Biotechnology’s experimental Covid-19 therapy, sotrovimab, for nearly $1bn.

Previous page 1 2 Next page